Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

November 27, 2018

Primary Completion Date

August 29, 2019

Study Completion Date

August 29, 2019

Conditions
Prostate CancerProstate AdenocarcinomaProstate Cancer RecurrentProstate Cancer Metastatic
Interventions
DRUG

18F-DCFPyL

A single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL

DIAGNOSTIC_TEST

PET/CT Imaging

PET/CT imaging will be acquired 1-2 hours post-PyL injection

Trial Locations (14)

10065

Memorial Sloan Kettering Cancer Center, New York

19104

University of Pennsylvania, Philadelphia

21287

Johns Hopkins University, Baltimore

33612

Moffitt Cancer Center, Tampa

48109

University of Michigan, Ann Arbor

52242

University of Iowa, Iowa City

53705

University of Wisconsin, Madison

63110

Washington University - Mallinckrodt Institute of Radiology, St Louis

90048

Tower Urology, Los Angeles

91010

City of Hope National Medical Center, Duarte

94143

University of California San Francisco - Helen Diller Cancer Center, San Francisco

94305

Stanford, Stanford

06520

Yale University, New Haven

G1R2J6

Chu de Quebec - Universite Laval, Québec

All Listed Sponsors
lead

Progenics Pharmaceuticals, Inc.

INDUSTRY

NCT03739684 - Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer | Biotech Hunter | Biotech Hunter